Active Ingredient History
Linsitinib is an experimental drug candidate for the treatment of various types of cancer. It is an inhibitor of the insulin receptor and of the insulin-like growth factor 1 receptor (IGF-1R). This prevents tumor cell proliferation and induces tumor cell apoptosis. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adrenocortical Carcinoma (Phase 3)
Breast Neoplasms (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Squamous Cell (Phase 1/Phase 2)
Carney Complex (Phase 2)
Chondrosarcoma (Phase 2)
Colorectal Neoplasms (Phase 1)
Gastrointestinal Stromal Tumors (Phase 2)
Head and Neck Neoplasms (Phase 2)
Liver Neoplasms (Phase 2)
Multiple Myeloma (Phase 1/Phase 2)
Neoplasms (Phase 2)
Ovarian Neoplasms (Phase 1/Phase 2)
Pancreatic Neoplasms (Phase 1/Phase 2)
Paraganglioma (Phase 2)
Pharmacokinetics (Phase 1)
Prostatic Neoplasms (Phase 2)
Sarcoma, Ewing (Phase 2)
Skin Neoplasms (Phase 1/Phase 2)
Small Cell Lung Carcinoma (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue